Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine

Immunology Letters

Volumn 161, Issue 1, 2014, Pages 20-30

  Ohtake, Junya ^a   Ohkuri, Takayuki ^a   Togashi, Yuji ^b   Kitamura, Hidemitsu ^a   Okuno, Kiyotaka ^c   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Bioimmulance Co   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; H K HELP; Survivin; Th1 and Tc1

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IRINOTECAN; MONTANIDE ISA 51; PACLITAXEL; PICIBANIL; PIRARUBICIN; SURVIVIN HELPER KILLER HYBRID EPITOPE LONG PEPTIDE; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; EPITOPE; IMMUNOLOGICAL ADJUVANT; INHIBITOR OF APOPTOSIS PROTEIN; PEPTIDE; SUBUNIT VACCINE; TUMOR ANTIGEN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CASE REPORT; CASE STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CERVICAL LYMPH NODE; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; MONOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; AMINO ACID SEQUENCE; BIOSYNTHESIS; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; HELPER CELL; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; PICIBANIL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SUBUNIT;

EID: 84899975521     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.04.010     Document Type: Article

References (43)

1. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
2. Hirohashi Y., Torigoe T., Maeda A., Nabeta Y., Kamiguchi K., Sato T., et al. An HLA-A24-restricted cytotoxic T lymhocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002, 8:1731-1739.
3. + T cells in anti-tumor immune responses. Immunol Rev 2008, 222:129-144.
4. + helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med 1989, 169(2):457-467.
5. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999, 190:617-627.
6. Nishimura T., Nakui M., Sato M., Iwakabe K., Kitamura H., Sekimoto M., et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000, 46:S52-S61.
7. Chamoto K., Wakita D., Narita Y., Zhang Y., Noguchi D., Ohnishi H., et al. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res 2006, 66:1809-1817.
8. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
9. Okuno K., Sugiura F., Hida J.I., Tokoro T., Ishimaru E., Sukegawa Y., et al. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med 2011, 2:73-79.
10. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
11. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8:351-360.
12. Voskens C.J., Sewell D., Hertzano R., DeSanto J., Rollins S., Lee M., et al. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 2012, 34:1734-1746.
13. Phan G.Q., Touloukian C.E., Yang J.C., Restifo N.P., Sherry R.M., Hwu P., et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 2003, 26:349-356.
14. van Poelgeest M.I., Welters M.J., van Esch E.M., Stynenbosch L.F., Kerpershoek G., van Persijn van Meerten E.L., et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013, 11:88.
15. Takahashi N., Ohkuri T., Homma S., Ohtake J., Wakita D., Togashi Y., et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 2012, 103:150-153.
16. Bachinsky M.M., Guillen D.E., Patel S.R., Singleton J., Chen C., Soltis D.A., et al. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun 2005, 5:6.
17. Monzó M., Rosell R., Felip E., Astudillo J., Sánchez J.J., Maestre J., et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999, 17:2100-2104.
18. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001, 95:92-95.
19. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000, 46:645-650.
20. Shen Y.C., Hu F.C., Jeng Y.M., Chang Y.T., Lin Z.Z., Chang M.C., et al. Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival. Cancer Epidemiol Biomarkers Prev 2009, 18:417-423.
21. Takeuchi H., Morton D.L., Elashoff D., Hoon D.S. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005, 117:1032-1038.
22. Liguang Z., Peishu L., Hongluan M., Hong J., Rong W., Wachtel M.S., et al. Survivin expression in ovarian cancer. Exp Oncol 2007, 29:121-125.
23. Lo Muzio L., Pannone G., Staibano S., Mignogna M.D., Rubini C., Mariggiò M.A., et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003, 89:2244-2248.
24. Ryan B., O'Donovan N., Browne B., O'Shea C., Crown J., Hill A.D., et al. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005, 92:120-124.
25. Nakajima F., Nakamura J., Yokota T. Analysis of HLA haplotypes in Japanese, using high resolution allele typing. MHC 2001, 8:1-32.
26. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
27. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625.
28. Noguchi M., Kobayashi K., Suetsugu N., Tomiyasu K., Suekane S., Yamada A., et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003, 57:80-92.
29. Masuzawa T., Fujiwara Y., Okada K., Nakamura A., Takiguchi S., Nakajima K., et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol 2012, 41:1297-1304.
30. Hattori T., Mine T., Komatsu N., Yamada A., Itoh K., Shiozaki H., et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009, 58:1843-1852.
31. Noguchi M., Mine T., Komatsu N., Suekane S., Moriya F., Matsuoka K., et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011, 10:1266-1279.
32. Nishikawa H., Kato T., Tawara I., Takemitsu T., Saito K., Wang L., et al. Accelerated chemically induced tumor development mediated by CD4+ CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A 2005, 102:9253-9257.
33. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
34. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
35. Takeshima T., Chamoto K., Wakita D., Ohkuri T., Togashi Y., Shirato H., et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 2010, 70:2697-2706.
36. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008, 358:2698-2703.
37. Kobayashi H., Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol 2008, 20:221-227.
38. Zhang Y., Wakita D., Chamoto K., Narita Y., Matsubara N., Kitamura H., et al. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol 2007, 19:151-161.
39. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
40. Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 2007, 110:203-214. Melanoma Study Group of the Mayo Clinic Cancer Center.
41. Ohkuri T., Wakita D., Chamoto K., Togashi Y., Kitamura H., Nishimura T. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br J Cancer 2009, 100:1135-1143.
42. Michaelsen T.E., Garred P., Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991, 21:11-16.
43. Bijker M.S., van den Eeden S.J., Franken K.L., Melief C.J., van der Burg S.H., Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 2008, 38:1033-1042.